{
  "ticker": "LLY",
  "target_date": "2025-07-24",
  "actual_date": "2025-07-24",
  "collected_at": "2025-12-08T12:03:21.329397",
  "price": {
    "open": 798.43,
    "high": 807.18,
    "low": 794.73,
    "close": 802.4862670898438,
    "volume": 2786400,
    "change_1d_pct": 0.82,
    "change_7d_pct": 4.36,
    "change_30d_pct": -0.22
  },
  "technicals": {
    "rsi_14": 57.23,
    "sma_20": 779.35,
    "sma_50": 766.4,
    "macd": 1.874,
    "macd_signal": 0.22,
    "macd_histogram": 1.655,
    "bb_upper": 803.71,
    "bb_lower": 754.98,
    "price_vs_sma20_pct": 2.97,
    "price_vs_sma50_pct": 4.71,
    "volume_ratio": 0.94
  },
  "fundamentals": {
    "market_cap": 892001386496,
    "pe_ratio": 48.752083,
    "forward_pe": 43.9113,
    "price_to_book": 37.46348,
    "price_to_sales": 15.011854,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.52,
    "pct_from_52w_low": 59.52
  },
  "macro": {
    "spy": {
      "price": 632.67,
      "change_1d_pct": 0.03,
      "change_7d_pct": 1.63
    },
    "vix": {
      "level": 15.39,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.41
    },
    "dollar_index": {
      "level": 97.38
    },
    "gold": {
      "price": 3371.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
      "source": "Yahoo",
      "datetime": 1753387472,
      "summary": "We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation\u2019s Substack. In this article, we will summarize the bulls\u2019 thesis on LLY. Eli Lilly and Company\u2019s share was trading at $798.89 as of July 23rd. LLY\u2019s trailing and forward P/E were 65.00 and 36.63 respectively accor",
      "url": "https://finnhub.io/api/news?id=ddc0477f2b31c985e9db2d509c7217e37eb6e596180b932cea4395f6485d426c"
    },
    {
      "headline": "Eli Lilly (LLY) Collaborates With Gate Bioscience For Innovative Molecular Gate Therapeutics",
      "source": "Yahoo",
      "datetime": 1753378513,
      "summary": "Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that potentially strengthens its innovative pipeline. During the same period, the FDA approved a label update for the company's Alzheimer's treatment, Kisunla, optimizing its dosing s",
      "url": "https://finnhub.io/api/news?id=7cf2e9ad7d2dc619ab4f77fd188f8e56d89197049fc2927d8f108dedfbb0962d"
    },
    {
      "headline": "The 3 Things That Matter for Eli Lilly Now",
      "source": "Yahoo",
      "datetime": 1753366500,
      "summary": "Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts.  The company's oral GLP-1 candidate will soon report key phase 3 results in weight management.  The drugmaker's shares look expensive, but the premium is justified given Lilly's prospects.",
      "url": "https://finnhub.io/api/news?id=82b5fa699ec1c6cd39981128d85d68d0a460b70c75145c1499c497db845b79cb"
    },
    {
      "headline": "This Weight-Loss Stock Sank After Earnings. It\u2019s Still a Risk for Eli Lilly, Novo Nordisk.",
      "source": "Yahoo",
      "datetime": 1753366200,
      "summary": "Viking Therapeutics  stock fell Thursday after it reported a widening quarterly earnings loss\u2014but that doesn\u2019t mean it won\u2019t eventually pose a threat to  Eli Lilly  and  Novo Nordisk  in the weight-loss drug market.  While the company has several weight-loss drugs in different stages of development,",
      "url": "https://finnhub.io/api/news?id=ab4bdb0ced10ccf05c0b11b4833d096f6d4c83716b9322a0c8ded90654878822"
    },
    {
      "headline": "How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?",
      "source": "Yahoo",
      "datetime": 1753365900,
      "summary": "LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.",
      "url": "https://finnhub.io/api/news?id=3b7ca2d9b2013ad37d57522728e29525f5e55b17922fe474c9a6de14a9684973"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753219662.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000196/xslF345X05/wk-form4_1753219662.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753217727.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000194/xslF345X05/wk-form4_1753217727.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753216439.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000188/xslF345X05/wk-form4_1753216439.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753215735.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000184/xslF345X05/wk-form4_1753215735.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753215620.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000182/xslF345X05/wk-form4_1753215620.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}